Human parainfluenza virus type 1 (hPIV-1) belongs to the Paramyxoviridae family (a family of single-stranded negative-sense RNA viruses) [1] . hPIV-1 (together with other types of hPIVs, for example, 2, 3 and 4) causes serious respiratory tract infections in infants, young children, the elderly and in immunocompromised hosts [1] . It is responsible for approximately 6% of paediatric hospitalizations [2] and is one of the principal aetiological agents of croup [3] . Although hPIVs have been known for more than 50 years, we still do not have specific and/or effective licensed therapeutics to manage these widespread pathogens. Because of the importance of the haemagglutinin-neuraminidase (HN) glycoprotein of hPIVs in membrane attachment, penetration of the cell surface and viral spread [1, 4, 5] , interest has focused on the development of selective inhibitors of this major surface glycoprotein.
Utilizing the three-dimensional structure of the HN protein of Newcastle disease virus (an avian paramyxovirus), which has conservation of the amino acid residues found around the active site among all parainfluenza viruses [6, 7] , a novel potent HN inhibitor (BCX 2798) was designed and proposed as an important advancement in the management of hPIV infections.
We previously demonstrated the high efficacy of BCX 2798 against hPIV-1 in in vitro assays and in the
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Efficacy of the novel parainfluenza virus haemagglutinin-neuraminidase inhibitor BCX 2798 in mice -further evaluation Introduction prophylaxis of a 90% lethal infection in mice with a recombinant Sendai virus, in which the HN gene was replaced with that of hPIV-1 (rSeV[hPIV-1HN]) [8] . The recombinant virus was designed specifically to develop an efficient read-out system to test BCX 2798 in vivo. Mice are poorly permissive to hPIVs, and infections of semipermissive laboratory animals (for example, hamsters and cotton rats) with hPIVs result in minimal lung pathology and an asymptomatic course of disease [1, [9] [10] [11] [12] . Infection of mice with rSeV(hPIV-1HN) has led to severe illness and robust replication of the virus in the lungs.
Prophylaxis will be important for management of hPIV infections, especially in immunocompromised hosts (for example, patients after bone marrow or solid organ transplantation or patients undergoing immunosuppressive therapy) because the level of mortality caused by hPIVs in this group reaches 30% [13] . To optimize the prophylaxis dosage regimen in our rSeV(hPIV-1HN) mouse model, we determined the efficacy of various single intranasal dosages of BCX 2798 against lethal recombinant virus infection in mice.
We also evaluated the efficacy of various intranasal dosages of BCX 2798 in 24, 48 and 72 h delayed treatment regimens against non-lethal rSeV(hPIV-1HN) infection. Our previously published findings showed that treatment of mice with BCX 2798 starting 24 h after 90% lethal infection with rSeV(hPIV-1HN) did not prevent death because of the high peak of viral titres (approximately 10 6 50% tissue culture infective dose [TCID 50 ]/ml) in the lungs at the start of treatment [8] . Because natural infections with hPIVs are unlikely to lead to death in immunocompetent patients [1, 14] , we developed a model of non-lethal rSeV(hPIV-1HN) infection in mice that represents an infectious dose of hPIV during human-to-human transmission and mimics the pattern of virus replication in the respiratory tract of non-immunocompromised humans [15, 16] .
To complete our evaluation of BCX 2798 in the rSeV(hPIV-1HN) mouse model, we assessed the applicability of oral, intramuscular, intraperitoneal and intravenous routes of BCX 2798 administration in the prophylaxis and therapy of rSeV(hPIV-1HN) infection in mice.
The results of our studies on the efficacy of the HN inhibitor BCX 2798 suggest that it is a promising candidate for clinical use in the effort to counter the effects of hPIVs that can cause severe respiratory diseases.
Methods
The HN inhibitor, BCX 2798 BCX 2798 (BioCryst Pharmaceuticals, Inc., Birmingham, AL, USA) is a derivative of Neu5Ac2en (2-deoxy-2,3-dehydro-N-acetylneuraminic acid), in which the O-4 hydroxyl group was replaced by an azido group and the methyl group of the acetamino moiety at C-5 was replaced with an isopropyl group [8] . BCX 2798, provided as a lyophilized powder, was solubilized in phosphate-buffered saline (PBS) before use in the in vitro and in vivo experiments described herein.
Cell cultures and viruses
LLC-MK 2 (monkey kidney epithelial) and 293T (human kidney epithelial; used for the rescue of rSeV[hPIV-1HN]) cells were grown in Dulbecco's modified Eagle's medium that contained 10% fetal bovine serum.
The rSeV(hPIV-1HN), which contains the hPIV-1 HN gene in place of the HN gene of SeV, was rescued from the full-length SeV complementary DNA genome pSeV(+) by using a reverse genetics process, as described previously [8] . The rescued virus was plaque-purified on LLC-MK 2 cells and amplified in embryonated chicken eggs. Sequence analysis of the HN gene of rSeV(hPIV-1HN) revealed no mutations.
The infectivity of the rescued viruses was determined using plaque assays. Briefly, LLC-MK 2 cells in six-well plates were inoculated with serial 10-fold virus dilutions. After incubation for 1 h at room temperature, the inoculum was removed and 1× minimum essential medium containing 2% bovine serum albumin and acetylated trypsin (5 µg/ml) mixed with 1% agarose was added to the plates. After 5 days of incubation at 33ºC, the second overlay, which consisted of minimal essential medium with 5% fetal bovine serum mixed with 1% neutral red and agarose, was added to the plates to help visualize plaques.
Drug studies in mice
Animal work was performed in a biosafety level 2 or higher facility at St. Jude Children's Research Hospital (Memphis, TN, USA) and approved by the institution's Animal Care and Use Committee. In the prophylaxis, 8-week-old female 129x1/SvJ mice (Jackson Laboratories, Bar Harbor, ME, USA) were anaesthetized via inhalation of isoflurane (2.5%; Baxter Healthcare Corporation, Deerfield, IL, USA) and inoculated intranasally with 4.2×10 7 plaque-forming units (PFUs; a 90% lethal dose) of rSeV(hPIV-1HN) in 50 µl of sterile PBS per mouse. Single and multiple (twice a day for 5 days) intranasal treatments of mice with 1 or 10 mg/kg/day of BCX 2798 in 50 µl of PBS were initiated 4 h before infection. Control animals were infected but were treated with PBS only. The efficacy of the compound in the prophylactic model was evaluated on the basis of reduction of virus titres in the lungs, prevention of weight loss and death, and survival rate determined 21 days after infection.
In the therapeutic model, mice were infected with 100 PFU per mouse of rSeV(hPIV-1HN) and treated intranasally twice a day with 0.1, 1 or 10 mg/kg/day of BCX 2798, starting either 24 or 48 h after infection (treatment for 5 consecutive days), or 72 h after infection (treatment for 4 consecutive days). The virus and compound volumes were similar to those used in the prophylaxis model. Activity of the compound in the therapeutic model was evaluated on the basis of reduction of the virus titres in the mouse lungs as well as the histopathological changes in the airways.
To control drug toxicity, five uninfected mice were given each tested dosage of compound and observed for survival, weight change and overt toxic effects for 21 days.
Assays of virus in mouse lungs
Lungs from three mice from each BCX 2798-or PBStreated group infected either with 100 or 4.2×10
7 PFU per mouse of rSeV(hPIV-1HN) were harvested 3, 5 or 7 days after infection and analysed to determine the virus growth. The procedure for lung suspension preparation was described in our previous report [8] . Virus titres (PFU/ml) were determined in LLC-MK 2 cells using plaque assays as described earlier. The mean virus titres ±se of the mean (±sem) are presented.
Analysis of residual drug activity
Lungs from three uninfected mice intranasally treated with 10 mg/kg/day of BCX 2798 with single or multiple regimens (twice a day for 5 days) or PBS were collected 7 days later. The residual drug activity in the lung suspension was determined by haemagglutination inhibition (HI) and neuraminidase inhibition (NI) tests.
HI tests
Lung suspensions were serially diluted (ratio 1:2) and the dilutions were preincubated with a standard dose of rSeV(hPIV-1HN) equal to four haemagglutination units for 1 h at room temperature. The mixtures were then incubated for 1 h at 4ºC with 0.5% chicken red blood cells. In a parallel HI test, activity of BCX 2798 against rSeV(hPIV-1HN) was evaluated. The concentration of the compound that showed 50% agglutination was considered the 50% inhibitory concentration (IC 50 ).
NI tests
The neuraminidase activity of rSeV(hPIV-1HN) was measured by a standard fluorometric assay using 2′-(4-methylumbelliferyl)-α-d-N-acetylneuraminic acid (Sigma Chemical Co., Saint Louis, MO, USA) as the substrate, as described previously [8] . In the NI test, lung suspensions were serially diluted (ratio 1:4) and 25 µl of each dilution was incubated for 1 h at room temperature with 25 µl of diluted virus at a standard amount of neuraminidase activity (200 relative fluorescence units). The reaction was initiated by the addition of substrate and stopped after 1 h of incubation at 37°C. In a parallel NI test, activity of BCX 2798 against rSeV(hPIV-1HN) was evaluated. The extent of NI was defined as the concentration of compound required to reduce the neuraminidase activity of the treated virus to 50% of that of the control virus. The IC 50 values were calculated by plotting the percentage of fluorescence inhibition relative to the control versus the log concentrations of the compounds.
Histopathological studies
Three mice from each BCX 2798-or PBS-treated group infected with 100 PFU per mouse of rSeV(hPIV-1HN) were euthanized 8 days after infection. The lungs were removed and processed for histopathological analysis as described previously [8] . Pneumonia was scored by an experienced veterinary pathologist (KLB) blind to the composition of the groups. The histopathology score (0-4) was assigned based on the following criteria: 0, no pathology; 1, minimal peribronchiolar and perivascular infiltrates of lymphocytes, plasma cells and few neutrophils, and rare extension of inflammation to alveoli; 2, mild peribronchiolar and perivascular leukocyte infiltration, mild airway epithelial hyperplasia with focal cell necrosis and localized intra-alveolar inflammation; 3, moderate peribronchiolar and perivascular leukocyte infiltration, moderate epithelial hyperplasia, necrosis medium and small airways, and locally extensive intra-alveolar inflammatory cell infiltrates; and 4, diffuse bronchointerstitial pneumonia. The mean score (±sem) for each group is presented.
Statistical analyses
The Kaplan-Meier method was used to estimate the probability of survival and the log-rank test was used to compare survival estimates for groups that received different treatments (BCX 2798 or control [PBS] ), that received treatment at different doses, and that received similar treatment using different regimens (single or multiple) over the period of 21 days. The mean days to death were estimated as the number of days that the mice survived after viral infection. If no death occurred during the observation period, the mean days to death was considered to be 21 days. An analysis of variance (ANOVA) model followed by Tukey's multiple comparison test was used to estimate and compare the virus lung titres and weight changes in the treatment groups. A P-value <0.05 was considered significant.
Results

Prophylactic efficacy of BCX 2798 in mice
We evaluated the prophylactic efficacy of the compound in a 90% lethal model of rSeV(hPIV-1HN) infection in mice.
Comparison of the survival curves for infected mice intranasally treated with 1 or 10 mg/kg/day of BCX 2798 at single or multiple dosages against survival curves for infected PBS-treated mice showed that both dosages administered on either regimen were protective against lethal infection with rSeV(hPIV-1HN) (P<0.05; Figure 1 ). However, the higher dosage of BCX 2798 was more effective than the lower dosage in terms of survival and weight loss (Table 1) . Thus, 10 mg/kg/day of BCX 2798 protected 90% of the mice (when given as a single dose) and 93.3% of mice (when given the compound for 5 days) from death, whereas in groups treated with 1 mg/kg/day, only 37.5% of mice in the single dosage treatment group and 42.9% of mice in the multiple dosage treatment group survived. Survival for the control group (infected but treated with PBS only) was 10%. Survival of mice appeared to correlate with weight loss. Mice that received 10 mg/kg/day of BCX 2798 on either regimen had a higher survival rate (at 21 days after infection) and less weight loss than those treated with 1 mg/kg/day of compound (either regimen) or PBS 5, 7 and 9 days after infection (P<0.05). There were no statistically significant differences in survival and weight loss between single and multiple intranasal prophylactic regimens with BCX 2798 at either dosage of 1 or 10 mg/kg/day.
Our previously published data showed that the antiviral effect of prophylactically intranasally administered BCX 2798 (10 mg/kg/day for 5 days) was associated with a significant reduction of rSeV(hPIV-1HN) in mouse lungs [8] . Analysis of the rSeV(hPIV-1HN) titres in the mouse lungs prophylactically treated with a single dosage of 10 mg/kg of compound showed that, similar to multiple administration, a single dose also significantly lowered recombinant virus titres in lethally infected mice compared with control mice (infected but treated with PBS only) 3, 5 or 7 days after infection (P<0.05; Figure 2) . Comparison of the virus lung titres between single and multiple intranasal prophylactic regimens with BCX 2798 at this dosage did not reveal significant differences. Analysis of residual drug activity in the lungs of uninfected mice treated with 10 mg/ kg/day of BCX 2798 with single or multiple regimens did not reveal any inhibitory activity in the lung suspensions on tested rSeV(hPIV-1HN) as compared with To compare the efficacy of different routes of BCX 2798 administration, we treated mice intranasally, orally, intramuscularly, intraperitoneally or intravenously with 10 mg/kg/day of compound twice a day for 5 days, starting 4 h before a 90% lethal infection with rSeV(hPIV-1HN). Our data (not shown) indicated that none, other than the intranasal route of compound administration, had significant effects on lethal rSeV(hPIV-1HN) infection in mice in terms of protection from weight loss and death or extension of mean days to death.
Therapeutic efficacy of BCX 2798 in mice
Our previously published data showed that the high level of viral titres (approximately 10 6 TCID 50 /ml) in the lungs at the start of treatment was a reason for a lack of BCX 2798 efficacy against a 90% lethal dose of rSeV(hPIV-1HN) when treatment of mice was delayed for 24 h [8] . Studies on experimental hPIV-1 infection in humans showed that the virus reaches the peak of its titres approximately 10 4.4 TCID 50 /ml in the human respiratory tract no earlier than 3 days after infection [16] . To develop a mouse model of parainfluenza virus infection that represents the course of hPIV-1 infection in humans, we determined the pathogenicity of the different doses (from 100 to 10 4 PFU) of rSeV(hPIV-1HN) in mice. Our data showed that infection of mice with 100 PFU of rSeV(hPIV-1HN) mirrors the kinetics of experimental hPIV-1 infection in humans with the highest level of rSeV(hPIV-1HN) titres in the mouse lungs of approximately 4.0×10 4 -5.0×10
5 PFU/ml observed on days 3-7 after infection (Figure 3) . The virus titres were lower than the assay detection limit (100 PFU/ml) at 1 and 9 days after infection (data not shown). The rSeV(hPIV-1HN) dose (100 PFU/ml) that was chosen for further experiments also correlated with evidence from studies in adult volunteers that the infectious dose of hPIVs is very small (<100 virus particles) [15] . This represents the first established mouse model of nonlethal infection for the evaluation of the therapeutic efficacy of HN inhibitors.
In this model, infected animals did not show signs of infection, such as weight loss or death; thus, the virus lung titres and histopathological changes in airways were the only parameters used for evaluation of activity of the compound in the therapeutic model. Figure 3 shows the efficacy of the different multiple dosages of intranasally administered BCX 2798 on the reduction of mouse virus lung titres in a therapeutic model. Our data indicated that the titres of the virus in the lungs of mice treated with the compound were lower than those in the control group (treated with PBS only) in a dose-and time-dependent fashion.
Treatment of rSeV(hPIV-1HN)-infected mice with BCX 2798 starting 24 h after infection significantly reduced the virus lung titres throughout the infection in all treated groups (P<0.05; Figure 3A) . The virus lung titres in infected untreated mice were 11-24-fold, 9-16-fold and 5-13-fold higher than in the groups treated with 10, 1 or 0.1 mg/kg/day of compound, respectively, at the same time points (3, 5 or 7 days after infection). Examination of the histopathological changes in the lungs of infected mice are shown in Figure 4 . The lungs of infected mice treated with PBS showed mild to moderate infiltrates of lymphocytes, plasma cells and macrophages around vessels and medium airways ( Figure 4C ) with a mean score of 2.0 (all mice scored 2 in this group; Figure 4D ). Focally extensive airway epithelial necrosis was observed in small and medium airways. By contrast, lungs from mice treated with 10 mg/kg/day of BCX 2798 had only minimal or no inflammatory response ( Figure 4B ) with a mean score of 0.7 (score range 0-1; Figure 4D ). When leukocyte infiltration was observed in the lungs of mice from this group, it consisted of low numbers of lymphocytes and plasma cells in perivascular and peribronchiolar spaces. No signs of lung inflammation were seen in mice in the uninfected control groups that received PBS ( Figure 4A ) or BCX 2798 only (data not shown).
Treatment of rSeV(hPIV-1HN)-infected mice with BCX 2798 starting 48 h after infection ( Figure 3B ) significantly reduced the virus lung titres throughout the infection only in the groups of mice treated with 1 or 10 mg/kg/day of the compound (P<0.05). The virus lung titres in untreated mice were 10-17-fold higher than those in the group treated with 10 mg/kg/day of compound and 4-10-fold higher than in mice receiving 1 mg/kg/day of BCX 2798.
Treatment with BCX 2798 starting 72 h after infection ( Figure 3C ) resulted in a significant reduction of virus lung titres only in mice treated with 10 mg/kg/day of the compound (P<0.05). The level of virus lung titres was approximately sevenfold higher in control mice than in treated mice both 5 and 7 days after infection.
Analysis of the efficacies of different dosages of BCX 2798 in the same therapeutic model showed that the higher dosage of the compound was more effective than the lower dosage in reducing mouse lung titres of rSeV (hPIV-1HN) (P<0.05) .
Comparison of the efficacies of similar dosages of BCX 2798 administered 24, 48 or 72 h after infection showed that initiating treatment earlier after infection was more effective at lowering mouse lung titres of rSeV(hPIV-1HN) than delaying treatment (P<0.05).
Studies on the efficacy of the single intranasal or multiple (during 5 days) oral, intravenous, intraperitoneal and intramuscular administration of 10 mg/kg/ day of the compound did not result in lower rSeV(hPIV-1HN) lung titres in infected mice in the 24 h delayed treatment model (data not shown). The results for BCX 2798 administered by other than intranasal route to mice The results of our current study indicate that BCX 2798, when administered intranasally, was effective for both prophylaxis and therapy of parainfluenza virus infection in mice.
Discussion
BCX 2798 represents a new class of antiviral compounds targeting parainfluenza virus HN. In this study, we first assessed the effectiveness of a single intranasal dose of compound in the prophylaxis of lethal rSeV(hPIV-1HN) infection and multiple intranasal doses in the treatment of non-lethal infection in mice. Similar to our previously published results [8] , BCX 2798 was well tolerated by mice during the treatment and post-treatment periods at all tested dosages (0.1-10 mg/kg/day). We found that single intranasal doses of 1 or 10 mg/kg were as efficacious as a multiple intranasal dosage regimen in preventing weight loss and death in infected mice. Previously, the high efficacy of a single dose of drug administration in reducing weight loss and death in lethally infected mice was reported for the influenza virus neuraminidase inhibitor peramivir [17] .
A dosage of 10 mg/kg/day of BCX 2798 prophylactically administered to mice using either regimen also significantly reduced virus lung titres, but 1 mg/kg/day did not. The high level of variability within the group of mice treated with 1 mg/kg/day of BCX 2798 (60% of them died and 40% survived) might be why statistical significance was not achieved with the number of mice used in the virus lung titre analysis. When virus lung titre is the only parameter for evaluation of drug efficacy (as in our non-lethal model of rSeV[hPIV-1HN] infection), expansion of animal resources might be the solution. We tested prophylactic efficacy of 1 mg/kg/ day of BCX 2798 (single versus multiple regimen) in the lethal model of rSeV(hPIV-1HN) infection. Thus, in addition to the virus lung titres, the weight change and death parameters enabled us to conclude that 1 mg/kg/ day was protective in this model and to determine that a single intranasal dose was as efficacious as a multiple intranasal regimen.
The therapeutic efficacy of BCX 2798 was tested in a non-lethal model of rSeV(hPIV-1HN) infection in mice. Because of the moderate level and steady rate of virus replication in the mouse lungs, weight loss and death did not occur in infected animals; thus, our evaluation of BCX 2798 efficacy was limited to comparing the virus lung titres and histopathological changes in airways of treated and untreated groups of mice.
Our data showed that only multiple administration of BCX 2798 for 5 consecutive days significantly reduced virus lung titres in infected mice in the therapeutic model, with the lowest effective dosage being 0.1 mg/ kg/day administered intranasally 24 h after infection. The greatest reduction of virus titres in the lung, accompanied by only minor or no histopathological changes, was observed with the highest tested dosage of 10 mg/kg/day administered intranasally 24 h after infection. This indicates that the combination of a high dosage of the compound with an earlier start of treatment might be the most effective regimen in the HN inhibitor application.
We noted a similar level of virus lung titres (approximately 10 4 PFU/ml) in mice treated with different dosages in the same treatment model or similar dosages administered in different treatment models at 7 days after infection (Figure 3 ). This phenomenon could be a result of the involvement of the immune response (in addition to antiviral activity of the compound) in lowering virus lung titres at this time point; however, we did not address this issue here. Further studies are required to understand how the HN inhibitor and immune system cooperate during parainfluenza virus infection. 
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Our previous study focused on the efficacy of the intranasal route of BCX 2798 administration [8] because the respiratory tract is the site for parainfluenza virus replication. However, studies with influenza virus neuraminidase inhibitors indicate that respiratory infection can also be effectively inhibited by oral (oseltamivir) [18] or intramuscular (peramivir) [17, 19] drug administration. Our current study showed no efficacy, other than that of the intranasal route, of BCX 2798 delivery on rSeV(hPIV-1HN) infection in mice. This indicates that nasal administration might be the first choice for effective delivery of BCX 2798 in clinical trials.
Overall, the results reported here suggest that BCX 2798 is a potent parainfluenza virus HN inhibitor that showed high efficacy in the prophylaxis and therapy of rSeV(hPIV-1HN) infection in mice. In addition, our in vitro and in vivo studies on the isolation of parainfluenza virus variants with decreased susceptibility to BCX 2798 indicate that resistance to parainfluenza HN inhibitors does not develop easily in either cell culture or in an animal model. Of the 100 virus clones isolated in LLC-MK 2 cells from the lungs of the rSeV(hPIV-1HN)-infected mice prophylactically treated with BCX 2798, only one clone possessed a drug-resistant substitution (N173S) on its HN [20] . This indicates a low possibility of drug-resistant virus emergence and enhances the idea that HN inhibitors have clinical potential. Introduction of this novel class of antiviral compounds into clinical practice might significantly broaden resources available to control hPIV infections.
